B of A Securities Maintains Buy on Day One Biopharmaceutical, Lowers Price Target to $25

Benzinga · 01/07 17:51
B of A Securities analyst Alec Stranahan maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and lowers the price target from $28 to $25.